

FRIULCHEM HAS SUCCESSFULLY COMPLETED THE REVAMPING PROJECT OF THE PRODUCTION SITE AND THE INSTALLATION OF A PHOTOVOLTAIC SYSTEM IN FRIULI VENEZIA GIULIA

Milan, 20 March 2024 - Friulchem S.p.A. (EGM: FCM), an innovative SME and one of the main Italian operators active at the international level in R&D and in third-party manufacturing services as a Contract Development and Manufacturing Organization (CDMO) of semi-finished and finished products containing active pharmaceutical ingredients and food supplements, with a particular specialisation in drug delivery for the veterinary sector, is delighted to announce that it has successfully completed the revamping project of the pharmaceutical production department at its Italian plant located in Friuli Venezia Giulia.

The revamping work began last summer after being postponed due to challenges related to the Covid-19 pandemic.

The main objective of this ambitious project was to increase the production capacity and productivity of the plant while simultaneously improving the quality level per the latest GMP standards. This will allow Friulchem to strengthen its presence in the international market, acquiring new customers and creating new products.

The revamping of the pharmaceutical production department was completed, allowing a complete reorganization of the production of veterinary pharmaceutical products.

Friulchem can now satisfy the growing demand for veterinary pharmaceutical products, making the most of the increased capacity and reducing unit production costs.

A further intervention that has been carried out is the commissioning in December 2023 of a photovoltaic system adjacent to the Vivaro (Pn) factory, which allows both to cover the system's daily needs and contribute to the environment by reducing our impact.

This vital step marks a new chapter in the evolution of Friulchem and confirms its commitment to excellence in veterinary pharmaceutical production.

The press release is available on the website <https://friulchem.com/it/media-relations/>

Friulchem (EGM:FCM), active for over 25 years in this industry, is now one of Italy's leading CDMOs (Contract Development and Manufacturing Organizations) operating internationally in the healthcare sector through third-party research, development and manufacturing services for semi-finished and finished products, containing both active pharmaceutical ingredients and food supplements, with particular specialisation in veterinary drug delivery systems, which, along with the development of dossiers for generic medicines for human use, represents Friulchem's field of excellence. Friulchem is an innovative SME and B2B company with an appreciable customer focus. It has solid Italian roots thanks to its production plant in Vivaro (Pordenone) and its administrative headquarters in Milan. The Company is strongly R&D-oriented and has established relationships with leading multinationals in the pharmaceutical industry.

ISIN Ordinary shares IT0005378457

Friulchem S.p.A.

ir@friulchem.com

Tel: +39 02 36591450

CFO SIM S.p.A. – Euronext Growth Advisor

ecm@cfosim.com

Tel: +39 02 30343 1